Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas

Roberto Andres Salas Fragomeni; Joshua R. Menke; Matthias Holdhoff; Clare Ferrigno; John Joseph Laterra; Lilja B. Solnes; Mehrbod S. Javadi; Zsolt Szabo; Martin G. Pomper; Steven P. Rowe

doi:10.1097/RLU.0000000000001769

Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas

Roberto Andres Salas Fragomeni, Joshua R. Menke, Matthias Holdhoff, Clare Ferrigno, John Joseph Laterra, Lilja B. Solnes, Mehrbod S. Javadi, Zsolt Szabo, Martin G. Pomper, Steven P. Rowe

School of Medicine

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

Original language	English (US)
Pages (from-to)	e433-e435
Journal	Clinical nuclear medicine
Volume	42
Issue number	10
DOIs	https://doi.org/10.1097/RLU.0000000000001769
State	Published - Oct 1 2017

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000001769

Cite this

@article{127b959a6e864f8388f2658ea5c8276e,

title = "Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas",

abstract = "High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.",

author = "{Salas Fragomeni}, {Roberto Andres} and Menke, {Joshua R.} and Matthias Holdhoff and Clare Ferrigno and Laterra, {John Joseph} and Solnes, {Lilja B.} and Javadi, {Mehrbod S.} and Zsolt Szabo and Pomper, {Martin G.} and Rowe, {Steven P.}",

year = "2017",

month = oct,

day = "1",

doi = "10.1097/RLU.0000000000001769",

language = "English (US)",

volume = "42",

pages = "e433--e435",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas

AU - Salas Fragomeni, Roberto Andres

AU - Menke, Joshua R.

AU - Holdhoff, Matthias

AU - Ferrigno, Clare

AU - Laterra, John Joseph

AU - Solnes, Lilja B.

AU - Javadi, Mehrbod S.

AU - Szabo, Zsolt

AU - Pomper, Martin G.

AU - Rowe, Steven P.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

AB - High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

UR - http://www.scopus.com/inward/record.url?scp=85025693590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025693590&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001769

DO - 10.1097/RLU.0000000000001769

M3 - Article

C2 - 28737579

AN - SCOPUS:85025693590

SN - 0363-9762

VL - 42

SP - e433-e435

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 10

ER -

Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this